News tagged with alzheimer s disease
Researchers make key discovery in fight against Alzheimer's disease
Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.
Alzheimer's disease & dementia
Dec 11, 2012 |
4.8 / 5 (5) |
1
|
Study: 'ApoE is an ideal target for halting progression of Alzheimer's disease'
Despite researchers' best efforts, no drug exists that can slow, halt or reverse the onslaught of Alzheimer's disease. A progressive and fatal neurodegenerative disorder, Alzheimer's has stolen the memories and livelihoods ...
Alzheimer's disease & dementia
Dec 05, 2012 |
5 / 5 (1) |
0
|
Alzheimer's disease in mice alleviated promising therapeutic approach for humans
Pathological changes typical of Alzheimer's disease were significantly reduced in mice by blockade of an immune system transmitter. A research team from Charité - Universitätsmedizin Berlin and the University ...
Alzheimer's disease & dementia
Nov 25, 2012 |
5 / 5 (10) |
0
|
New evidence on easing inflammation of brain cells for Alzheimer's disease
New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease ...
Alzheimer's disease & dementia
Oct 03, 2012 |
5 / 5 (1) |
0
Alzheimer's disease: preventative measures can delay onset
"We cannot prevent Alzheimer's, but we can delay the onset of the disease until an advanced age with the right measures," says Peter Dal-Bianco, Alzheimer's expert from the MedUni Vienna's University Department ...
Alzheimer's disease & dementia
Sep 21, 2012 |
5 / 5 (1) |
0
Investigators identify gene linking cataracts and Alzheimer's disease
In a recent study, investigators at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) identified a gene linking age-related cataracts and Alzheimer's disease. The findings, published online in PLoS ON ...
Genetics
Sep 11, 2012 |
5 / 5 (2) |
0
New diagnostic biomarkers offer ray of hope for Alzheimer's disease
Alzheimer's disease (AD) is one of the most common brain disorders, with an estimated 35 million people affected worldwide. In the last decade, research has advanced our understanding of how AD affects the brain. However, ...
Alzheimer's disease & dementia
Aug 30, 2012 |
not rated yet |
0
|
Are the eyes the key to a new test for Alzheimer's disease?
(Medical Xpress)—A simple eye tracking test could hold the key to earlier Alzheimer's diagnosis, according to new research published in the Journal of the American Aging Association.
Alzheimer's disease & dementia
Aug 23, 2012 |
not rated yet |
1
Brain enzyme is double whammy for Alzheimer's disease
The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed ...
Alzheimer's disease & dementia
Aug 20, 2012 |
5 / 5 (3) |
0
|
Is too much brain activity connected to Alzheimer's disease?
High baseline levels of neuronal activity in the best connected parts of the brain may play an important role in the development of Alzheimer's disease. This is the main conclusion of a new study appearing in PLoS Computational Bi ...
Alzheimer's disease & dementia
Aug 16, 2012 |
5 / 5 (2) |
0
Blood test for Alzheimer's gaining ground
The possibility of an inexpensive, convenient test for Alzheimer's disease has been on the horizon for several years, but previous research leads have been hard to duplicate.
Alzheimer's disease & dementia
Aug 09, 2012 |
3.7 / 5 (3) |
0
|
Epilepsy drug levetiracetam reverses memory loss in animal model of Alzheimer's disease
Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer's-related impairments in an animal model of the disease.
Alzheimer's disease & dementia
Aug 06, 2012 |
5 / 5 (4) |
1
|
Alzheimer's cognitive decline slows in advanced age
The greatest risk factor for Alzheimer's disease (AD) is advancing age. By age 85, the likelihood of developing the dreaded neurological disorder is roughly 50 percent. But researchers at the University of California, San ...
Alzheimer's disease & dementia
Aug 02, 2012 |
5 / 5 (1) |
0
|
Spice ingredient in curry emerges as promising basis for an Alzheimer's disease medicine
The spice compound that gives curry dishes their yellow color and pungent flavor is emerging as a prime candidate for a less expensive treatment for Alzheimer's disease (AD), according to an article in the current edition ...
Alzheimer's disease & dementia
Aug 01, 2012 |
not rated yet |
1
Anti-tau drug improves cognition, decreases tau tangles in Alzheimer's disease models
While clinical trial results are being released regarding drugs intended to decrease amyloid production - thought to contribute to decline in Alzheimer's disease - clinical trials of drugs targeting other disease proteins, ...
Alzheimer's disease & dementia
Jul 19, 2012 |
not rated yet |
0
Alzheimer's disease
Alzheimer's disease (AD), also called Alzheimer disease, Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer's, is the most common form of dementia. This incurable, degenerative, and terminal disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him. Generally it is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. An estimated 26.6 million people worldwide had Alzheimer's in 2006; this number may quadruple by 2050.
Although each sufferer experiences Alzheimer's in a unique way, there are many common symptoms. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. In the early stages, the most commonly recognised symptom is memory loss, such as difficulty in remembering recently learned facts. When a doctor or physician has been notified, and AD is suspected, the diagnosis is usually confirmed with behavioural assessments and cognitive tests, often followed by a brain scan if available. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown, long-term memory loss, and the general withdrawal of the sufferer as their senses decline. Gradually, bodily functions are lost, ultimately leading to death. Individual prognosis is difficult to assess, as the duration of the disease varies. AD develops for an indeterminate period of time before becoming fully apparent, and it can progress undiagnosed for years. The mean life expectancy following diagnosis is approximately seven years. Fewer than three percent of individuals live more than fourteen years after diagnosis.
The cause and progression of Alzheimer's disease are not well understood. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit; no treatments to delay or halt the progression of the disease are as yet available. As of 2008, more than 500 clinical trials were investigating possible treatments for AD, but it is unknown if any of them will prove successful. Many measures have been suggested for the prevention of Alzheimer's disease, but their value is unproven in slowing the course and reducing the severity of the disease. Mental stimulation, exercise, and a balanced diet are often recommended, as both a possible prevention and a sensible way of managing the disease.
Because AD cannot be cured and is degenerative, management of patients is essential. The role of the main caregiver is often taken by the spouse or a close relative. Alzheimer's disease is known for placing a great burden on caregivers; the pressures can be wide-ranging, involving social, psychological, physical, and economic elements of the caregiver's life. In developed countries, AD is one of the most economically costly diseases to society.
For more information about Alzheimer's disease, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.